CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone lymphoma, according to a recent clinical trial published in The Lancet. Marginal zone lymphoma ...
Mar 4, 2026
0
6
The U.S. Food and Drug Administration has approved a new indication for Breyanzi (lisocabtagene maraleucel) for treating adults with marginal zone lymphoma (MZL) who have failed treatment or relapsed after two or more prior ...
Dec 15, 2025
0
8
Measuring the lymphocytes—white blood cells that fight infection—in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to research from physicians ...
Dec 8, 2025
0
12
New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor (CAR) T cell therapy, ...
Dec 8, 2025
0
10
In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community setting on an outpatient basis, patients with relapsed or refractory large B-cell lymphoma (LBCL) responded ...
Sep 30, 2024
0
38
Mantle cell lymphoma (MCL) is a rare and sometimes ruthless form of non-Hodgkin lymphoma. Even when treatment appears to be successful, the cancer often returns and is difficult to cure.
Aug 2, 2024
0
54
CAR T-cell therapy is an effective treatment for aggressive subtypes of follicular lymphoma, according to a clinical trial published in Nature Medicine.
Jul 18, 2024
0
52
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed ...
Mar 19, 2024
0
56
A two-year follow-up clinical trial found that a new personalized cellular therapy treatment for relapsed or refractory B-cell lymphoma demonstrated strong safety and improved overall survival in patients, according to findings ...
Feb 27, 2024
0
43
Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published online Dec. 28 in Blood ...
Jan 4, 2024
0
16
